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Abstract On May 9–10, 2011, the Walter Reed Army Insti-
tute of Research, as the Army Center of Excellence for Infec-
tious Disease, assembled over a dozen leaders in areas related
to research into the communities of microorganisms which
colonize and infect traumatic wounds. The objectives of the
workshop were to obtain guidance for government researchers,
to spur research community involvement in the field of trau-
matic wound research informed by a microbiome perspective,
and to spark collaborative efforts serving the Wounded War-
riors and similarly wounded civilians. During the discussions,
it was made clear that the complexity of these infections will
only be met by developing a new art of clinical practice that
engages the numerous microbes and their ecology. It requires
the support of dedicated laboratories and technologists who
advance research methods such as community sequencing, as
well as the kinds of data analysis expertise and facilities. These
strategies already appear to be bearing fruit in the clinical
management of chronic wounds. There are now funding
announcements and programs supporting this area of research
open to extramural collaborators.
The US military has engaged in active ground combat for
the last several years; common patterns of combat injury
include closed head trauma, explosive injury to the limbs,
and significant gunshot wounds. As attempts are made to
save life and limb, open traumatic wounds are colonized by
assemblages of organisms and become vulnerable to serious
infections.
On May 9–10, 2011, the Walter Reed Army Institute of
Research (WRAIR), as the Army Center of Excellence for
Infectious Disease, assembled over a dozen leaders in
areas related to research into the communities of micro-
organisms which colonize and infect traumatic wounds.
The objectives of the workshop were to obtain guidance
for government researchers, to spur research community
involvement in the field of traumatic wound research
informed by a microbiome perspective, and to spark col-
laborative efforts serving the Wounded Warriors and sim-
ilarly wounded civilians. The two-day meeting included
presentations of medium length, lunch presentations, and
moderated discussions, interspersed with relatively lengthy
opportunities for questions and open discussion. Presenters
were given topics. The complete agenda as executed is
attached as Table 1, and attendees are listed in Table 2.
Not every attendee was able to be present for the entire
workshop.
This workshop was critical because no published re-
search has described or addressed the entire suite of organ-
isms colonizing traumatic wounds, despite a significant
body of published research investigating chronic comorbid
wounds (diabetic ulcers, pressure ulcers, venous stasis
ulcers, etc.). Attendees from various government research
communities also participated in the discussions. The work-
shop was supported by the WRAIR commander, funded by
the Science Director, and organized by the Department of
Wound Infections within the Center of Excellence in Infec-
tious Diseases (Bacterial Diseases Branch). The workshop
was recorded, both in audio and video, and the presenters
were asked to release the presented materials under a Crea-
tive Commons License (attribution). With the exception of a
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few particular slides, the materials were so released. Record-
ings exist at the WRAIR; requests for viewing will be
considered individually.
Early indications are that this workshop was a success.
The latest findings, new to many in the room, were dis-
cussed. The attendees offered candid, current commentary
and opinion. Potential collaborations were discussed among
military and civilian research scientists, program officers,
leaders, and participating clinicians.
Introduction
The initial presentations by Capt. Daniel, Deputy Command-
er, Medical Research and Materiel Command (MRMC), and
Col. Craft, Director, Department of Wound Infections, Bacte-
rial Diseases Branch, WRAIR, set the context of the meeting.
Capt. Daniel described the context of the MRMC research
efforts within the military medical system. Unlike a company
that requires a product to sell, the military medical research
“business model” includes the patient. Thus, the military
jointly focuses on fielded medical materiel and fielded medi-
cal knowledge: the answer to military medical needs can be
either a product or a doctrine. Each is validated and tested
before being put into practice. Medical products are approved
by the FDA before being passed to the military clinician;
Table 1 Agenda as performed
Monday, May 9, 2011
7:00 a.m. to 7:45 a.m. Breakfast
8:00 a.m. Posting of the Colors
8:05 a.m. to 9:00 a.m. Capt. Daniel, MRMC Deputy
Commander: Wounded Warriors
Col. Craft: Welcome to the WRAIR
9:00 a.m. to 9:30 a.m. Presentations: Wound Microbiomes:
J. Zenilman
9:30 a.m. to 10:00 a.m. Presentations: Traumatic Wound
Microbiome: E. Grice
10:00 a.m. to 11:00 a.m. Presentations: The Wound in Context:
M. Blaser
11:00 a.m. to 11:30 a.m. Presentations: Exploring Microbial
Diversity using Next-Generation
Sequencing: M. Sogin
11:30 a.m. to 12:00 a.m.
12:00 a.m. to 1:00 p.m. Lunch Discussion: HMP, L. Proctor
1:00 p.m. to 3:00 p.m. Discussion: Genome, Metagenome,
Community: Interpreting Complex
Data Types in the Clinic
W. Nierman, H. Ochman, C. Liu
3:00 p.m. to 3:30 p.m. Coffee Break
3:30 p.m. to 5:30 p.m. Discussion: Data Tools and
Computational Challenges
O. White, L. Price, R. Knight
5:30 p.m. to 7:30 p.m. Dinner
Tuesday, May 10, 2011
6:00 a.m. to 8:00 a.m. Breakfast
8:00 a.m. to 9:00 a.m. Presentation The Polymicrobial
MDRO Infection: D. Relman
9:00 a.m. to 10:00 a.m. Presentation Wound Community
Remediation: S. Dowd
10:00 a.m. to 11:00 p.m. Presentation Molecular Wound
Diagnostics: P. Murray
11:00 a.m. to 12:00 p.m. Lunch Presentation: Novel
Therapeutics and the FDA,
MAJ Smith
12:00 p.m. to 2:00 p.m. Brainstorming Structured
Collaborations: Col. Craft
2:00 p.m. to 2:30 p.m. Coffee Break
2:30 p.m. to 3:00 p.m. Remarks: Col. McNabb, DBRD
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fielded knowledge, such as clinical practice guidelines, is
passed through peer review and clinical trials before fielding.
Capt. Daniel described the research (under the Principal As-
sistant for Research and Technology) and development arms
(under the Principal Assistant for Acquisition) of the MRMC,
the several laboratories and their international detachments,
and the contracting and advanced development units. These
are significant to scientists because the MRMC provides a
mechanism to move basic research through advanced devel-
opment, fielding, and acquisition by the military. The core
programs (Military Infectious Disease, Combat Casualty
Care, Military Operational Medicine, and Clinical and Reha-
bilitative Medicine) were each presented briefly, demonstrat-
ing the breadth of the MRMC interests and the segments into
which the military medical research is conceptually divided.
Col. Craft, Director, Department of Wound Infections at
the WRAIR, discussed the clinical and historical context of
the meeting. His discussion began with the increase in
injuries and wounds in the Iraq and Afghanistan theaters
[1, 2]; moved to the clinical laboratory response to an increase
in Acinetobacter isolations reported in MMWR (http://
www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a1.htm);
and discussed the epidemiological research that followed,
pointing to a nosocomial spread of the Acinetobacter isolated
from patients [3]. He also described the five levels of care in
the military health care system [4] and the deployed clinical
laboratory, including the microbiological test menu and the
microbiology augmentation kit for the combat support hospi-
tals. The vision of the Department of Wound Infections with
regard to the progression of traumatic wound infections was
presented (Fig. 1). Finally, he described the research and
policy endeavors in the Department of Wound Infections
funded under the Military Infectious Disease Research Pro-
gram. The Department has substantial breadth in its intramural
research program and extramural partnerships, including re-
search on the molecular pathogenesis of specific mutidrug-
resistant organism (MDRO) nosocomial bacteria, the commu-
nity of organisms in a wound, and the host response to the
infection. Antibiotic usage policies in the military and antibi-
otic resistance frequency among clinical isolates featured
prominently in the question and answer session.
Presentations
Collectively, the Monday morning presentations brought to-
gether the latest published and unpublished insights into the
human microbiome in the context of a critical clinical need.
Dr. Zenilman, the Director of Infectious Disease at Johns
Hopkins Bayview, reviewed the epidemiology, microbiology,
and community ecology of chronic wounds on an inpatient
service, leveraging his clinical experience and relevant re-
search, while noting the distinction between those and trau-
matic wounds. In Baltimore, hyperendemic comorbidities
such as geriatrics, diabetes, and obesity are closely associated
with chronic wounds. Burns are another common clinical
presentation which Dr. Zenilman discussed. The wounds as-
sociated with these comorbidities include venous hyperten-
sion, diabetic, decubitus (pressure), and arterial insufficiency
ulcers. These ulcers are particularly long-lasting, are always
colonized by bacteria, require debridement, and frequently do
not respond well to antibiotic chemotherapy.
Dr. Zenilman posed a broad list of clinical and scientific
questions in four areas: descriptive epidemiology, ascertain-
ment methods, etiology, and rational wound management.
He particularly focused on the development of rational
therapies and clinical practice guidelines. He described the


















Figure 1 Traumatic wound
infection progression. A flow
diagram representing the
progression of disease or
healing from the time of
traumatic wounding through the
available stages of infection.
Red lines represent the
unchecked progression of
disease; blue, the progress
towards healing; green, the
process of successful
interventions; brown, the
process of largely unsuccessful
interventions
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The major clinical practice question raised by Dr. Zenilman
was the distinctions among infection, wound healing “ar-
rest,” and colonization. In response to attendee questions, he
affirmed that there is still no concrete understanding of
which bacteria prevent wound healing and how they do so.
The evidence Dr. Zenilman presented was a mixture of
clinical photos, sequencing data, culture data, and PCR data.
Clinical photos provided by Cmdr. Elster, Naval Medical
Research Center, demonstrated the difficulty clinicians face
in generating an accurate prognosis of wound healing.
Quantitative culture and PCR had each demonstrated that
most wounds were polymicrobial, including gram-negative
putative pathogens and anaerobes. Sequencing data reinfor-
ces the conclusion that the chronic wound flora is always
diverse. Fluorescent in situ hybridization refuted the usual
objections that raw DNA may be biasing the molecular tests.
It also demonstrates the spatial structure of the community.
Dr. Zenilman also mentioned the clinical importance of
biofilms with regard to antimicrobial resistance, persistence,
quorum sensing, and inflammatory deregulation. Finally, he
observed that with spatial structure comes the ability to
establish different microenvironments, including anaerobic
zones. A commonality between chronic wounds and bacte-
rial vaginosis was noted; a joint association via anaerobiosis
was hypothesized.
Dr. Zenilman provided detailed guidelines for sampling
the wound microbiome based on pilot experiments and
personal experience. He discouraged swab sampling and
encouraged the taking of a 5–7-mm curette sample (20 mg
of tissue) with viscous xylocaine on the leading edge of the
wound for clone libraries, quantitative culture, or PCR.
Taking these samples did not appear to impact wound heal-
ing. Swab results and curette results did not correlate with
each other and particularly did not accurately preserve the
105 CFU qualitative swab cutoff between “contamination”
and “critical colonization” [5]. Sampling location (rim to
center, rim to rim) by curette did not change the flora
recovered by culture or metagenomics. Swabs are only used
clinically by Dr. Zenilman for detecting MRSA.
Dr. Zenilman discussed a broad range of studies, includ-
ing Maryland ICU surveillance data (active surveillance;
Lucy Wilson, culture and PFGE) and a longitudinal study
of several burn patients in which antibiotics were used. In a
striking fashion, Dr. Zenilman moved fluidly among data
collected via clinical microbiology (culture), PCR, and se-
quencing. This was notable because when close compari-
sons were made, the results were not usually the same—the
organisms identified by culture, sequencing, and PCR are
different. In particular, culturing identifies a subset of the
population, but no algorithm exists to predict which taxa
are overlooked or the phenotypes of those unidentified
organisms. The shifting basis for claims—such as state-
ments about the frequency of infections caused by certain
organisms, with particular resistance patterns, as compared
to statements about not understanding the cause of infec-
tions or being able to determine which wounds were in fact
infected—passed largely unnoted. Clinicians in particular
appeared comfortable with this kind of discourse, bridging
the gap between different epistemological strategies and
hypotheses regarding wound infections.
Dr. Grice, of the National Human Genome Research Insti-
tute, presented her insights into the interaction between cuta-
neous tissue and the microbiome of traumatic and chronic
wounds, derived from animal studies on traumatic and diabet-
ic wounds in a mouse model [6]. During the presentation, she
eschewed culture results entirely after an initial slide demon-
strating that culture did not capture the diversity of the skin
flora. Dr. Grice demonstrated that the normal flora of the
genetically diabetic mouse skin is significantly divergent, in
quantity and composition, from the normal flora of the het-
erozygous control mouse. The diabetic mouse skin bears more
bacteria overall, especially Staphylococcus. Immediately fol-
lowing wounding, the alpha diversity in the wound quickly
declines and then recovers. The wound flora in each mouse
begins relatively similar but then diverges (Fig. 2). Dr. Grice
interprets this as the wound “selecting” for a certain commu-
nity. In the normal wound, healing occurs despite a heavy
population of Staphylococcus initially, replaced by Clostridia
and diverse minor populations. The groups that are apparently
underrepresented in the healing wound are the beta-
proteobacteria and actinobacteria. In the diabetic mouse, the
wound becomes chronic. Dr. Grice hypothesizes that this is
the result of an inflammatory feedback loop that is proteolytic
and oxidative, preventing healing, limiting the natural innate
debridement, and leading via re-epithelialization (not contrac-
tile healing, which is the primary mechanism of healing in the
nondiabetic mouse) to a hyperkeratonic, flakey skin with a
deficit of hair follicles and a susceptibility to rewounding.
Rewounding leads to a chronic non-healing wound.
The study of healing in a mouse model required some
defense precisely because of the role of contractile healing
in the mouse, as opposed to the human. Healthy humans
primarily re-epithelialize. These differences clearly limit the
direct application of the mouse wound model to the evalu-
ation of human wound therapies.
Dr. Grice also discussed the mouse gene expression pro-
files that accompanied healing in her wound infection mod-
el. In the healthy mouse, the gene expression profiles follow
the expected pattern of immune activation and deactivation.
Key groups of genes include those for the immune response,
keratinocyte regeneration, and extracellular matrix produc-
tion. In the diabetic and non-healing wounds, some genes
fail to turn off by day 14; their activation levels mirror the
relative abundance of Staphylococci.
Dr. Grice requested that the community provide more
support for the analysis of longitudinal data sets; increase
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the study of colonization and small-scale microbial migra-
tion; and integrate microbial genetic studies with host gene
expression studies, particularly with respect to TLR4 and
other immune genes.
Dr. Blaser, the Frederick H. King Professor of Internal
Medicine at New York University (NYU), provided a wide-
ranging, data-rich presentation of the skin microbiome. Re-
search by groups with which he is affiliated is rapidly
translating the basic awareness of the skin microbiome
structure into a clinically relevant understanding of pathol-
ogy by way of clinical investigations. During his presenta-
tion, Dr. Blaser provided a focused review of the skin
microbiome literature, including interpersonal, intersite and
bilateral variation, and the distribution of common bacterial
and fungal taxa. He raised the question of skin biotypes a
la Arumugam [7] and discussed the results of microbiome
studies comparing populations from different communi-
ties, including a city in Colorado, New York City, and an
Amazonian village.
Dr. Blaser discussed some methodological innovations
and concerns. One innovation was the use of eukaryotic
DNA quantification to provide a standard allowing the
relative quantification of bacterial DNA between samples
[8]. Using skin swabs, the variability of the eukaryotic to
bacterial DNA concentrations is approximately two orders
of magnitude; this may correlate with actual bacterial cell
density on the skin surface. The use of different 16S rRNA
primers was also discussed in some detail; the results from
V1–V3 and V3–V5 do not lead to the same conclusions. In
presenting a psoriasis project [in collaboration with Barbara
Methe of J. Craig Venter Institute (JCVI)], Dr. Blaser pre-
sented both the V1–V3 and V3–V5 results without neces-
sarily privileging either one. In later discussion, Dr. Sogin
stated that the agreement was actually rather good, and some
suggestion was made that the paucity of V1 data in the
reference databases was the source of the discrepancy—and
would be resolved with growth in the metagenomic databases.
Dr. Blaser discussed several pathogenesis-related studies,
including ongoing studies of psoriasis vulgaris and skin
abscesses. Both studies are large and complex, requiring
multidisciplinary teams to encompass the clinical interface,
pathology, microbiology, dermatology, statistics, and infor-
matics. Initial results of the psoriasis study clearly demon-
strate the complex interplay of the flora and the immune
system in this disease (or diseases). Initial studies on skin
abscesses have encompassed some culture-negative infec-
tions as well as several seemingly MSSA- and MRSA-
dominated infections. There are 25 patients enrolled, with
age-matched controls. This ongoing study will attempt to
understand these abscesses, in particular in relationship to
the local skin flora.
Dr. Sogin, of the Marine Biological Laboratory, pre-
sented his insights on the long-tailed operational taxonomic
unit (OTU) abundance distribution present in many, if not
most, natural environments. The long-tailed diversity distri-
bution in microbial ecology is a unifying principle that
raises general questions, requires common methodological
approaches, and is of practical importance in all environ-
mental engineering applications, including the practice of
medicine.
The first question almost always raised by the observa-
tion of long-tailed diversity descriptions is whether the
observation is accurate. Dr. Sogin reviewed the history of
that discussion, with particular reference to Quince et al. [9],
Reeder and Knight [10], Quince et al. [11], McClellan et al.
[12], and Huse et al. [13]. By way of this review, he presented
evidence that the long-tailed distributions of OTU diversity
are real and that they comprise 70 % of the diversity in many
Longitudinal  relative abundance of major 
















Figure 2 Comparison of
traumatic and diabetic wound
progression. A graph
demonstrating the difference in
wound community composition
between wounds in diabetic
and nondiabetic mice over a
28-day period
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environments (soil, water). Further, he presented methodo-
logical innovations which may be missed by the naïve re-
searcher, in particular the use of pyronoise/ampliconoise and
chimera detection to clean up sequencing errors and the
difficulties with transitive alignments, resolved through pre-
clustering and average neighbor-based cluster building meth-
ods to assign sequences to accurate OTUs. He used these
methods to analyze experimental data which were mis-
characterized using other methods and then applied them
to environmental data sets to validate the observations of
long-tailed distributions, to determine how best to treat
singletons (most appear to be real and cannot safely be
discarded as erroneous).
Dr. Sogin briefly discussed the implications of long-
tailed distributions for ecological theory, including the ques-
tion of what rare organisms were “doing” in the samples.
Recent evidence points to migration from habitats in which
the species are common and periodic spikes in abundance
for many of the rare taxa; however, other theories, such as
keystone species being rare for community structural rea-
sons even in their primary environment, are also supported
in some cases. The implications of rare taxa in wound
infection diagnostics and therapeutics are still very much
unknown.
Finally, Dr. Sogin presented CLASI-FISH, which allows
one to interrogate very diverse samples microscopically. By
using fluorophores on multiple probes in all possible combi-
nations, dozens, even hundreds, of distinct OTUs can be
observed in a single sample. Recourse to microscopy provides
a control against sequencing error but also allows observation
of community microstructure and a link to cell morphology.
This very exciting method and the colorful images produced
incited vibrant discussion.
Dr. Lita Proctor, Director of the Human Microbiome
Project from the National Institutes of Health (NIH), spoke
during lunch. She provided a high-level view of the NIH
Human Microbiome Project (HMP; $175 M program) and
many of its early successes, including insights into micro-
biome diversity, function, and development [14]. The Hu-
man Microbiome Project itself has funded foundational
initiatives across the field, including the creation of a basic
reference genome dataset, the creation of readily accessed
data analysis software/pipelines, and the establishment of
the Data Analysis and Coordination Center. At the time of
the presentation, there were 2 clinical sampling centers, 4
sequencing centers, 9 demonstration projects, 10 computa-
tional tools projects, 15 technology development projects,
and 5 ethical/legal/social projects funded by the HMP.
Now-classic results produced by the HMP describe the
ubiquitous, shared, identifiable, body site specific, age spe-
cific, human microbiota. In fact, differences among the
microbiota of different body sites swamp the variability
derived from other factors such as age, gender, and culture.
Among these, she highlighted the gut microbiota as the
“cardinal microbiota,” (Fig. 3) structured differently among
people into discrete types of communities to extract the
maximum amount of energy from their environments. Some
exciting new data indicate that horizontal gene transfer rates
GI microbiome as ‘cardinal’ microbiome.
Microbiome with most microbiota
Metabolic capacity of the liver
“Microbial organ” (11th organ system)
Systemic effects (e.g.gut/brain axis)
Communicates with the other 
microbiomes
Figure 3 The cardinal
microbiome. A slide illustrating
the GI tract and describing
the gut microbiome as central
among the several human-
associated microbiomes
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are elevated in the host-associated microbiome relative to
air, soil, and marine microbiomes (cited personal communi-
cation 2011 from Eric Alm, MIT; now published [15]); this
has interesting implications as one might consider megafau-
na to be spatial hotspots for the generation of genomic
diversity within their own habitats. Her major conclusions
from the HMP Demonstration projects were that novel
disease-associated communities with specific compositions
have been described, with both structural and functional
genetic markers, and that these findings permit a better
understanding of certain diseases as well as the development
of new diagnostic tools.
The afternoon consisted of a series of shorter presentations
in a matrix of discussions. The presentations were separated
into two groups of three. Dr. Nierman of the JCVI presented
an overview of the JCVI HMP portfolio, including collabo-
rations with NYU, NIAID, University of Illinois, the Mayo
Clinic, Johns Hopkins, McGill, Dow, RTI, Howard Universi-
ty, National Jewish Health, NIDCR, NIDDK, TEDDY,
USCD, and Children’s NationalMedical Center; investigating
diseases including esophageal cancer, bacterial vaginosis,
psoriasis, obesity, colon cancer, asthma, periodontitis, diabe-
tes, UTIs, and febrile illnesses. Despite the number of diseases
mentioned, the entire presentation was framed by a review of
the normal microbiome and the commensal role of bacteria in
human immunity and metabolism (Fig. 4). This is a particu-
larly notable perspective when a disease may be caused by an
absence of some microbial colonization or exposure, as op-
posed to a standard germ hypothesis embodied in Koch’s
postulates, in which the presence of microbial colonization
is the cause of a clinical condition or disease.
Dr. Nierman moved quickly to discussing the probiotic
notion, which is a joint causal relationship in which a disease
is caused by pathogen presence but potentiated by commensal
absence; Candida albicans infections, cystic fibrosis (CF),
and asthma were all fingered as diseases which may follow
this paradigm (naturally, CF is even earlier potentiated by a
genetic problem, Candida infections were created experimen-
tally in gnotobiotic animals, and asthma may have other
underlying causes upstream of the alterations in the lung
microbiome). The pattern appears to be a decline in diversity
followed by invasion by a pathogen.
Asthmatics follow this pattern during their frequent lung
infections. Crohn’s lesions also follow this pattern [16].
Artificially enriching the populations prior to clinical dis-
ease may offer the potential to ameliorate such disorders, but
broad application of probiotics requires significant learning
about the host system, the commensals, and the pathogen.
Dr. Ochman, of Yale University, delivered a biphasic pre-
sentation beginning with his perspective on the state of micro-
biome studies and ending with a data-rich preview of research
being conducted using archived chimpanzee fecal samples. In
the initial phase of his presentation, Dr. Ochman distributed a
handout listing the current software he uses to manipulate
microbiome data; given the audience, this was less an act of
information and more an act of demonstration. The point
made was that other scientists approach researchers with
microbiome experience asking: what should I do with my
data? This is unusual because most areas of science do not
allow for the successful accumulation of data in the absence of
the training to analyze it. However, sequencing technologies
have now created a situation in which amplicon sequence data
are available; and there is a perception by those not actively
engaged in the field that there is one pipeline, one set of tools,
and one “answer” while, in Dr. Ochman’s words, “nothing is
further from the truth.” He further emphasized that most
“microbiome” studies currently published are actually “micro-
biota” pattern descriptions and do not provide extensive ex-
planation of the biological processes leading to the observed
abundance, diversity, and distribution.
The second phase of Dr. Ochman’s presentation de-
scribed a fascinating project built on the samples collected
during prior chimpanzee studies. Of 100 chimpanzees stud-
ied, he focused on 35, for which the demographics and
genetics are well understood. The chimpanzees’ parentage,
community affiliation, geography, and diet have been stud-
ied already; fecal samples have been collected and stored in
freezers. Some samples had been studied in an attempt to
understand the origins of HIV. The samples span seasons,
migrations, generations, and regions. There are apparently
no true “infant” samples which have been studied, but
animals of both genders and several ages have been studied
over the course of several years. These are habituated ani-
mals and have not been treated with antibiotics.
Qin et al. 2010 
Principal Component Analysis
Bacterial Species Abundance
Figure 4 Distinctions among healthy and disease-associated flora. A
two-axis principal component analysis derived from sequencing ele-
ments of the intestinal flora in healthy persons and those suffering from
chronic gastrointestinal disease. Clearly the distributions are different,
though there is some overlap in these first two principal components
between the healthy flora and the ulcerative colitis flora
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Preliminary observations revealed first that the chimpan-
zee hindgut flora is distinct from that of humans and other
primates. Surprisingly, there was no detectable signal of host
genetic relatedness; geography, gender, community member-
ship, and diet featured prominently in explaining microbiota
composition. Migration events were detectable in the data.
Further findings are expected as additional samples are pro-
cessed under Dr. Ochman’s “clone by phone” process.
Dr. Liu, of Translational Genomics Research Institute
(TGen), presented some insights into the translation of micro-
biome research to clinical applications. As a clinician, she
addressed a communication challenge that faces many puta-
tive next-generation diagnostics; that is, the advocates for
those diagnostics regularly emphasize difficulty in communi-
cating with the physicians with whom they must continue to
interact, and whom will eventually be executing many of the
plans and programs which are proposed by practitioners in
other communities. The content of her talk emphasized how
clinicians are integrated into diverse clinical scenarios and
healthcare settings; how they will need to develop either a
subspecialty in each area that integrates and interprets ge-
nomic, metagenomic, community, ecological, or evolutionary
data for the larger specialty, or how a new service will be born,
similar to radiology or microbiology, to perform that task for
the entire practicing medical community. Decisions like these
will interact strongly with the level of complexity that is
accepted from the diagnostic instruments and tools them-
selves; open-ended platforms provide highly complex data,
possibly at a significant delay, but with the ability to address
unknown or unacknowledged scenarios. These “discovery”
systems may be used by teams of specialists, or they may
remain in the research laboratories. On the other hand, closed
approaches which sort among previously characterized possi-
bilities are generally amenable to direct interpretation by a
single specialist or even the clinician himself. As Dr. Liu
emphasized, this bypasses complex bioinformatics, sensitivity
issues, and zebra chasing.
Dr. Liu made the point that researchers would profit the
medical community more by educating physicians and devel-
oping systems in partnership with clinicians; more bidirec-
tional learning and interdisciplinary education, and mutual
respect. She suggested that genomic medicine, possibly even
ecology, should be integrated into the medical curriculum
soon, to prepare physicians for the tools of 5 years from
now; this includes integrating this material with the board
examinations and the gatekeepers that drive “average” medi-
cal education today.
A lively discussion followed the talk; one area that re-
ceived significant discussion was the idea, put forward by
Dr. Liu, that some direct physiological measurements might
be more useful than genetic or genomic data. Dr. Proctor
suggested using serum as an integrating signal, a form of
metabolomics. One idea presented was that therapeutics
could be piloted ex vivo before being introduced into
patients. Dr. Sogin registered skepticism because of the time
frame (missing ecology and evolutionary potential) and the
lack of biological context; Dr. Gancz suggested that such a
model would at least provide another term in the approxi-
mation for the real system by moving beyond pure cultures
to consortia, embracing signaling and co-metabolism on a
short time scale. Dr. Proctor reminded the group of the long
history environmental engineers have using black box mi-
crobial assemblages and how they are related to the current
fecal transplant research and brainstorming conducted by
Linda Chrisey and her team at the Office of Naval Research.
Dr. Knight introduced some research results suggesting that
transplanting new functionality into a gut by transplanting
flora did not succeed when the goal was to allow mice to
degrade cellulose in conjunction with termite flora.
Dr. White, of the Institute for Genome Sciences, University
of Maryland Baltimore School of Medicine, is the principal
investigator at the Human Microbiome Project Data Analysis
and Coordination Center (DACC). He presented his vision for
how the DACC can serve the needs of the wound microbiome
research community. His statements about the data-intensive
nature of microbiome research reinforced the experience of all
the active researchers in the room. The HMP presents a salient
case of what has been popularly called the data tsunami. The
DACC deals with a “scary” data management problem, as-
sembling vast quantities of data from numerous sources into
one mutually informative warehouse for the research commu-
nity. No single researcher has the persistent capability to
generate, process, store, and analyze his own data robustly;
some researchers specialize in sample acquisition, others in
sequencing, while still others produce software pipelines to
perform the analysis. Many times these researchers are not
even members of the same groups, institutions, or even re-
search communities. The DACC provides interfaces between
datasets, software utilities, and computing resources to allow
researchers to access the products of other research groups
without undue friction. It also collaboratively produces the
standards, documents, SOPs, and workflows required to sup-
port inter-institutional collaborations.
The HMP has made substantial use of the DACC.
Unlike many prior projects which could have benefitted
from a similar center but did not, the funding to establish
the DACC was designed into the original HMP scope of
project—and the utility of the DACC will extend long
beyond the end of the initial HMP. The goal is a system
which allows meaningful comparisons among data sets
generated for different purposes, in a scalable, elastic,
accessible, persistent, and efficient form. Dr. White sees
the path to this goal as leading through the development
of the Open Science Data Framework, which provides
flexible interfaces (APIs) to underlying “infrastructure as
a service” and, ultimately, “data as a service.”
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In the vision presented by Dr. White, rigorous agreements
about data types (both experimental and intermediate ana-
lytical results) are the structure on which the entire commu-
nity can hang its own contributions. These agreements are
generated by consortia of active researchers and supported
by standards and documentation. Data flow into a common
data store and can be analyzed through different shared
algorithms and viewed in various aspects to answer distinct
questions. Intermediate calculations—particularly intensive
ones, such as genome assembly—can be stored centrally to
support these various analytical strategies (termed “reusable
results”). At the same time, competing algorithms which
reach similar classes of results can be applied in parallel,
as they suit different needs in the community.
This vision is one of a mature community and field of
endeavor with common kinds of questions and unique
resources pooled in a novel way. Dr. White presented some
technical information about the current and near-term state
of affairs, including the intervening months between the
presentation and this publication, but ultimately he was
conveying a sweeping view of the road ahead and suggest-
ing the scope and scale at which the community can come
together to support common methods and resources.
Dr. Price of the TGen introduced the material and digital
systems which TGen is developing to manage complex
genetic, genomic, and metagenomic research and clinical
programs. The material systems include kits (bar coded)
sent to sample providers, a sample repository, a “biorefi-
nery” (laboratory for specimen preprocessing), and sequenc-
ing/data collection facilities. Software mirrors this structure
with modules for specimen tracking, clinical information
management, laboratory information management, and
genomics information management (the BMS, CIMS,
LIMS, and GIMS) all built on a data warehouse (Bio4D)
and tied to an interactive data portal. The system is portable,
built on Java, and compliant with data security and infor-
mation assurance standards. It is already being used in
studies, including one on the microbiota of burn patients.
The software is not currently freely distributed, but accord-
ing to Dr. Price it may be licensed from TGen.
Dr. Knight, of the University of Colorado, finished the first
day by discussing analytical tools as applied to microbial
community data. His focus on visualization tools provided a
graphically engaging presentation. The underlying package he
employed is QIIME (free to the public), an integrated pipeline
which allows the analysis and visualization of 16S rRNA
sequence data from mixed bacterial communities, metage-
nomics data, and, with some tweaking, related data types
(for instance, functional gene sequences).
Driving the need to analyze and visualize vast amounts of
sequence data is the decline in sequencing costs. In the Knight
Laboratory, sequencing costs are now eclipsed by DNA ex-
traction as the major cost behind community analysis, in part
because Illumina is the primary sequencing technology
employed [20], with barcoded samples. The expected cost of
sequencing 96 samples for 16S rRNA genes is expected to fall
to $1,000 with the advent of the GS Junior, dropping below
the costs of laboratory preparation.
Perhaps in contrast to some of the published literature and
even other speakers, Dr. Knight was unequivocal that the cost
of data analysis is not a major issue. Using QIIME to perform
the kinds of analyses he presented is computationally inex-
pensive; unlike de novo genome assembly, for example. Giv-
en the low cost of sequencing and the low cost of data
processing, the remaining issues tend to be sample collection,
hypothesis generation, and experimental design—in short, the
hard work of science.
Sample collection as a difficulty can be split into two
parts: sample management and metadata collection. Most
researchers have less difficulty than does Dr. Knight with
sample collection; however, he discussed his Earth Micro-
biome Project, with a current expected cache of 40,000
samples and an eventual goal of processing 200,000 sam-
ples. These samples, along with the Human Microbiome
Project samples and other samples from other studies, are
meant to allow a researcher to view their own study samples
in the context of a universe of other samples. This presents
challenges. From a sample management perspective, Dr.
Knight discussed working backwards from the microbial
sequence data to identify a mislabeled sample. On the other
hand, the data that come along with the samples are critical;
Dr. Knight discussed the difficulties in acquiring good meta-
data and finding well-structured databases of clinical data.
The spread of good database practices and metadata stand-
ards (such as well-managed electronic health records) would
do much to advance the field of microbial ecology and to
allow its direct application to human health.
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Realizing this vision requires relatively rigid standards to
manage data types and processes, especially when the un-
derlying technologies and algorithms are constantly shifting.
The distinctions between data generation technologies
(sequencing technologies, for example) are generally ac-
knowledged, and their various merits are often debated. In
addition, the algorithms used in each stage of the data
analysis may appear similar but conceal critical distinctions.
Many groups are currently contributing software to the
microbiome community; several are also serving as aggre-
gators and developing architectures to perform integrated
data analyses. Examples of software packages which are
currently available and being supported are CLoVR [17],
MG-RAST [18], and Quantitative Insights Into Microbial
Ecology (QIIME) [19]. These packages each provide pipe-
lines that vertically integrate different analysis tasks, from
cleaning up sequence data through assigning operational
taxonomic units to generating dynamic visualizations of
the data.
The studies Dr. Knight presented included the biogeog-
raphy study of keyboards and fingertips, the geography of
the face, a time-series study of several individuals at 27
body sites, and a time-series analysis in which mice bearing
humanized gut flora were fed different diets to monitor
weight gain. Principal coordinate analysis featured promi-
nently as an analytical tool, and supervised classification
techniques are now becoming prominent in the Knight Lab-
oratory. Most striking in the presentation and in some recent
publications, videos which allowed an additional dimension
to be visualized were both revealing and convincing; as
always, data presentation is a rhetorical art.
Dr. Relman, of Stanford University, used an ecological
framework to provide a theoretical framework for under-
standing wound infections. He explicitly integrated island
biogeography into the discussion, including assembly rules,
migration rates, and inter/intraspecific competition/coopera-
tion. This biogeography has been best explored at the level of
the individual, particularly during the primary succession
events of the infant gut. This critical succession may be one
of the only primary successions which occur on a spatial/
temporal scale similar to the events following a major trau-
matic injury or critical burn. Research by Palmer et al. [14]
and Dominguez-Bello [21] has described the opportunist
exposures that lead to the early flora, such that some infant
gut microbiota most resemble maternal gut flora, others ma-
ternal vaginal flora, and still others, maternal skin flora—in
part due to the birth process, which differs between vaginal
birth and surgical birth. Recent publications suggest that this
infant gut flora may have long-term health implications for
the individual, giving direct clinical relevance to research of
this kind [22].
At a very different scale, Dr. Relman also discussed the
repeatable distinctions among the microbiota populating dif-
ferent facets of individual tooth surfaces [23]. On work of this
scale, the quality of the sequence was absolutely critical. Each
site was found to be a nonrandom subset of the mouth diver-
sity. There was no obvious lateral symmetry, though disease
tends to be symmetric. Migration appears to play very little
role in populating tooth surfaces.
No study of landscape ecology would feel complete
without a discussion of anthropogenic meddling; filling
this important trope for wound ecology is a discussion of
antibiotic treatment. The discussion launched from the
work of Jernberg [24] and Dethlefsen [25, 26], highlight-
ing the long-term impact of antibiotic treatment, the impact
of repeated antibiotic treatment, and the question of com-
munity resilience or lack thereof. The general conclusion
was that there were long-term effects; that repeated shocks
increased the impact of the perturbation such that resilience
was lost before the community composition changed rad-
ically; and that based on functional gene studies, there
were likely to be biochemical functions impacted in the
later shifts, though phylogeny seemed to change more than
biochemistry did.
Ultimately, the translation of the methods of biogeography
into the study of traumatic wounds brings a rich tradition of
questions, tentative answers, debates about theory, results, and
conclusions into a clinical setting. It raises questions about
assembly rules, assemblage composition, community func-
tion, ecosystem services, resilience, and ultimately the re-
sponse of the whole (eukaryotic and microbial) host; and
provides strategies to approach their answer through natural
and anthropogenic experimentation in the same way that
island biogeography and landscape ecology have been ex-
plored, particularly in the five decades following McArthur’s
pioneering work.
From this perspective, Dr. Relman concluded that though
the community is collecting vast amounts of microbiome
data, deficiencies in study design may compromise its value.
He emphasized the need for carefully managed time courses
and structured metadata, a theme that recurred elsewhere.
Dr. Relman’s clinical experience provided an interesting
counterpoint to his research perspective. From a research
perspective, he discussed the complexities of bacterial com-
munities, antibiotic resistance [27–29], and the blinkered
view inherited by being informed solely with culture results;
but from the clinical perspective, in the short term, his
recommendation is the studious application of clinical art
to provide focused treatment to wounds with certain organ-
isms, to not cover everything, to ignore even “recognized”
and antibiotic-resistant “pathogens” depending on clinical
context and instinct. In particular, he recommended learning
from past experience and avoiding an antimicrobial game of
“whack-a-mole.” This very practical advice lent an earthy
tone to a talk otherwise deeply flavored by theory.
Dr. Dowd, currently with MR DNA aka Molecular Re-
search LP., spoke about his experience with chronic wound
diagnostics and therapeutics. His diagnostic group and the
associated clinic treat non-healing wounds such as diabetic,
decubitus, pressure, and vascular insufficiency ulcers, par-
ticularly infections that present limb, even life, risks. At the
time the practice opened, these wounds led to an amputation
rate of 100 %.
The current therapeutic strategy at the clinic centers on
debridement as the primary means of removing bacteria and
dead tissue [30–32]. Repeated debridement alone has a sig-
nificant positive impact on healing, particularly when com-
bined with the correction of systemic host factors (such as
blood glucose management). Besides this universal approach
to wounds, the clinic and diagnostic laboratories use molecu-
lar methods to determine the microbiota of each wound [33],
which inhabits the wound in a structured community [34]. The
therapeutic process that derives from the molecular diagnos-
tics includes local antibiotics applied within a 3-day window
of the debridement [35] to prevent reestablishment of the
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community. The current delivery mechanism is a lipogel [36]
which releases antimicrobials into the wound.
Molecular methods change the diagnosis of many infec-
tions [33]. Wounds that provided no culturable bacteria often
present numerous bacteria, including some expected to be
culturable (such asKlebsiella).Wounds which present a single
culturable organism instead present a complex community.
Many genera are missed frequently by culturing even when
numerically dominant in a wound. Streptococcus are the sec-
ond most commonmajor wound organism;Morganella, Fine-
goldia, Corynebacteria, and a range of anaerobes including
Bacteroides, Anaerococcus, Peptoniphilius, Clostridium, and
Actinomyces are also common. Naturally, Staphylococci, En-
terococcus, Serratia, Proteus, enteric bacteria, Acinetobacter,
Providencia, Pseudomonas, and yeast are still well repre-
sented. Some organisms are frequently misidentified, includ-
ing Peptoniphilus harei, Corynebacterium striatum, and
Prevotella. Ultimately, 86 % of the genera identified by mo-
lecular methods from a suite of chronic wounds could be
identified in clinical culture as well, when the laboratory used
sampling methods specific to anaerobes and used several
media and enrichment environments over a period of 4 weeks.
However, surgical site infections posed a unique problem;
frequently, the Bacteroides which dominated those wounds
required co-growth in a polymicrobial wound biofilm model
[37]. In 99% of wounds, 1 % of the population is easy to grow
and is characterized by routine clinical cultures [38].
As a result, the clinical diagnostics performed at the
wound care clinic substitute molecular methods for culture.
The initial method targets 27 organisms by qPCR and pro-
vides an answer in 24 h. Every 6 months, additional targets are
added to the qPCR assay. A second-level molecular assay is
driven by sequencing and reports bacterial identification
results in 48 h.
Molecular assays for fungi (18 s sequencing) report that
23 % of chronic wounds contain significant fungal popula-
tions, while typical literature rates of fungal co-infection are
2–3 % [39]. Additional co-infecting organisms include algae
and Cyanobacteria in certain patients. These do not seem to
inhibit healing. Other organisms not commonly treated in
wound clinics include some which apparently do need to be
treated, particularly Corynebacteria.
A retrospective study of 1,300 patients concluded that
wound management techniques at the clinic have improved
since 2007. Using culturing as a diagnostic tool appears to
impose a 30% penalty on time to heal. Focusing on the worst-
case patients, in the top 10 % of time to heal, healing time has
progressed from 150 days without molecular diagnostics or
topical antimicrobials to 62 days with only molecular diag-
nostics, and finally to 37 days with topical antimicrobials.
These statistics brought the talk around from the initial images
of debridement and patient infection to a more positive and
encouraging finale.
Dr.Murray, then-head of the ClinicalMicrobiology Service
in Department of Laboratory Medicine of the NIH, spoke on
the future of diagnostic wound microbiology. He discussed
the core of traditional wound diagnostic microbiology: mi-
croscopy, culture, susceptibility testing, and strain typing.
Innovations have been improving each of these, but they
continue to show serious weaknesses. Microscopy provides
limited, presumptive identifications and no sensitivity data.
Culture methods have many flaws which have been discussed
at length elsewhere. Susceptibility testing and biochemical
identification rest on a shaky foundation of culture, are less
accurate than normally acknowledged, and are slow. Finally,
strain typing methods—even MLST—have had serious flaws
revealed by whole genome sequencing; but sequencing itself
presents serious challenges, particularly with assembly and
interpretation.
Dr. Murray’s laboratory at the NIH has been investigating
a range of additional closed- and open-ended technologies,
including qPCR, microarrays, gene sequencing, whole ge-
nome sequencing, and proteomics. The laboratory has a
significant number of qPCR assays in support of research
protocols. In addition, gene sequencing (16 s rRNA, ITS,
and SecA) are used to provide identifications for uncommon
and slow-growing organisms. In particular, Nocardia and
Mycobacteria can be identified overnight directly from acid
fast-positive specimens. Filamentous fungi, which can eas-
ily be misidentified by microscopy alone, are also identified
by sequencing.
At Dr. Murray’s clinical laboratory, microbial whole ge-
nome sequencing is already used for certain outbreak anal-
yses (e.g., multidrug-resistant Acinetobacter baumanii). It is
particularly valuable when other methods of phylogenetic
reconstruction are discordant.
Proteomics, in particular MALDI-TOF, is a particular fa-
vorite for routine bacterial identifications because of the speed
and efficiency of the method. As the database grows, the
concordance with the gold standard identifications increases
steadily. At this time, it is at 98 % for bacteria and yeast
species [40–44]. Even the difficulties are now predictable;
foreseeable, reliable difficulties can be circumvented.
The method holds further promise for two reasons. First,
samples can be prepared directly from positive blood cul-
tures [45]. Secondly, there may be more information to be
gained from the same assays because the data currently
utilized are only a fraction of the available signal, albeit that
fraction with the lowest confounding noise relative to the
gold standards of identification. Using more of the peaks
which come from the TOF MS may allow for additional
information such as strain typing to be gleaned from the
same process.
In the immediate future, Dr. Murray expects gene sequenc-
ing to be displaced by proteomics and strain typing to move to
whole genome sequencing. Pathogenicity estimationmay also
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be addressed by these two methods. Deep sequencing of
communities will be used for quantification of organisms in
complex assemblages and pathogen discovery. Metabolomics
has potential to address questions of drug resistance, metabol-
ic activity, and virulence.
MAJ Smith, the Director of the Clinical Services Support
Division, U.S. Army Medical Materiel Development Activity
(USAMMDA), ended the talks by discussing the function of
USAMMDA in supporting medical research and product
development. USAMMDA currently has approximately 70
open applications with the FDA and provides an interface
between researchers, the military, and the FDA. It supports
diverse products including drugs, devices, prebiotics, vac-
cines, and any other regulated product. Her presentation
emphasized the need to address regulatory concerns early in
product development, particularly for FDA-regulated drugs,
devices, and biologics. She presented the nuts and bolts of
how the Army provides support to medical researchers as
they explore potentially fruitful concepts and later transition
their products to clinical trials and advanced development
(Fig. 5). In particular, addressing regulatory concerns early
keeps researchers out of trouble, limits rework, and enables
easy transitions to manufacturing. USAMMDA offers signif-
icant experience and support to researchers so that they need
not encounter the FDA alone or unprepared. She suggested
consulting USAMMDA for any militarily relevant medical
research effort prior to candidate selection (vaccine compo-
nents/raw materials; show-stopping issues like Ames scores;
testing requirements), while planning manufacturing, while
developing protocols for preclinical safety, and during pre-
IND/IDE planning. She gave some general advice on product
development and reminded the attendees that the US Military
only uses medical materiel under strict regulation; typically
only FDA-approved materials are used in medical care. The
regulation quoted was: “Personnel carrying out military oper-
ations shall be provided the best possible medical counter-
measures to chemical, biological or radiological warfare or
terrorism and other health threats. The DoD Components
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Figure 5 Synchronizing drug development among industry, the FDA,
and the DoD. This slide illustrates the different terminology and
classifications used to describe progress along the developmental
trajectory of a new drug. Each organization has distinct language and
key offices assist in liaison and coordination, without which the inter-
faces can be treacherous
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shall make preferential use of products approved by the FDA
for general commercial marketing, when available, to provide
the needed medical countermeasure.” In addition, though
USAMMDA is available to assist researchers, the Depart-
ment of Defense does not get special consideration or exemp-
tions from FDA regulations. Rather, it carries the additional
burden of complying with Federal and Department of De-
fense Acquisition Regulations. The Major’s talk was a fitting
conclusion to a series of presentations very much focused on
the hope of new diagnostics and therapeutics for the treatment
of combat-related wound infections.
Col. McNabb, Director of Bacterial Diseases at the
WRAIR, closed the conference with comments about the
collective need for a collaborative strategy to include research-
ers and clinicians. Following his comments, the group dis-
cussed potential collaborations before dispersing. Several of
the attendees already participate in the Human Microbiome
Project and have longstanding collaborations. In particular,
the community centers around several sequencing centers,
software development groups, and data analysis centers which
were represented at the workshop. The opportunity to intro-
duce more people into this community was one of the benefits
derived from the meeting.
Conclusions
The workshop was 2 days of intensive and wide-ranging dis-
cussion. Participating government researchers obtained guid-
ance, and the research community was encouraged to become
involved in the field of traumatic wound research. During the
discussions, it was made clear that the complexity of these
infections will only be met by developing a new art of clinical
practice that engages the numerous microbes and their ecology.
It requires the support of dedicated laboratories and technolo-
gists who advance research methods such as community se-
quencing, as well as the kinds of data analysis expertise and
facilities represented by the HMP DACC and TGen’s Bio4D
system. These strategies already appear to be bearing fruit in
the Research and Testing Laboratory, where the clinical man-
agement of chronic wounds has been improving steadily. There
are now funding announcements and programs supporting this
area of research open to extramural collaborators.
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